-
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
July 22, 2026 02:00 ET | Source: Healx Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination…
-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026 20:35 ET | Source: Mesoblast Limited NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L…
-
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – June 23, 2026 14:00 ET | Source: Coherus Oncology, Inc. REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech…
-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
-
Zuellig Pharma Unveils State-of-the-art Clinical Trial Support Innovation Center in South Korea to Support both Domestic and Global Clinical Research Needs
Gyeonggi-Do, South Korea Zuellig Pharma, a leading healthcare solutions company in Asia, today announced the grand opening of its new state-of-the-art Clinical Trial Support (CTS) Innovation Center in South Korea. The opening of this facility underscores Zuellig Pharma’s continued investment and commitment to advancing healthcare, reinforcing its position as a trusted regional partner in driving…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
